MiMedx sees FY25 revenue up mid-to-high teens percent range

Sees FY25 adjusted EBITDA margin at least in mid-20% range Capper continued, “As we await the final 2026 reimbursement rules from the Centers for Medicare and Medicaid Services, we are planning for a range of potential scenarios. We made certain recommendations to CMS during the comment period, which we believe will improve upon the proposed rules, if incorporated. Importantly, MIMEDX (MDXG) is well positioned to adapt, regardless of the outcome. We believe these reforms will have a much-needed stabilizing effect on our industry and are a net positive for US taxpayers, the Medicare Trust Fund, Medicare beneficiaries and for MIMEDX. As such, we continue to believe the long-term outlook for this Company is incredibly bright.”